Introduction: The soaring incidence of gout in the United Kingdom suggests that medical practitioners should be increasingly aware of optimizing management of gout, which is aimed at pain relief, preservation of joint function and preventing recurrent attacks. Recent guidelines published by the British Society of Rheumatology (BSR), have provided clinicians with a framework for achieving these aims.
Introduction
Gout, a disorder of purine metabolism, is characterized by hyperuricaemia and leads to deposition of uric acid crystals in joints, precipitating acute inflammatory arthritis, tophi around joints, and uric acid urolithiasis.
Gout has become the most common inflammatory arthritis, affecting 2.49% of the population. 1, 2 Over the past 16 years, its incidence has increased rapidly in the United Kingdom, and tends to increase with age, especially afflicting those above 65 years. 2, 3 Gout is more common in men, with an incidence of 4.42 per 1000 in men but 1.32 per 1000 in women. 4 The short-term management of gout is centred on pain relief and preservation of joint function while long-term management targets prevention of recurrent attacks and chronic joint damage. Patients presenting with mild gout symptoms are treated by self care and lifestyle modification, but for those with moderate to severe attacks, the addition of medication to treat gout is pivotal. 5 should:
 Have sUA levels tested since initiation of allopurinol  Have allopurinol dosages reviewed based on sUA  Achieve a sUA of < 300 μmol/ Patients who were on febuxostat (which is deemed an alternative to allopurinol) were excluded from Standard 2 as febuxostat was recently approved as a ULT but was not included into the BSR guidelines at the time of its publication.
10 Table 1 outlines the criteria involved in reference to the guideline published by the BSR. 7 
Search strategy
This audit was undertaken at a GP surgery in a suburban town in Greater Manchester.
Using the electronic patient database (EMIS Web) from the GP practice, a search was carried out to identify all patients who had a Read-coded diagnosis of "gout" and/or 
Results
A total of 112 patients with a diagnosis of gout were identified. See Table 4 for a summary of the audit results.
Demographics
Out of the 112 patients with gout, 87 patients (78%) were male and 25 patients (22%) were female ( Figure 2 ). The patients' ages ranged from 27 to 94 years.
Figure 2. Gender distribution of gout patients

Assessment of gout patients
All the patients were included to determine whether they had a 4-6 week review checking sUA. A total of 52 patients (46%) received appropriate review (Figure 3 ). 
No. of patients
Within 4-6 weeks 46%
Not within 4-6 weeks 54%
Patient review
NSAIDs 63%
Colchicine 17%
Steroids 2%
No medications 18%
Acute Management
Allopurinol 61%
Not on allopurinol 39%
Usage of Allopurinol
Monitoring of chronic gout
Among those on allopurinol, 42 patients (67%)
had their sUA checked monthly while 21 patients (33%) did not. Dose adjustments of allopurinol had been made in 20 patients (31%). 12 patients (19%) managed to achieve the target value sUA level of <300 μmol/L (Table 2) . patients (40%) had a sUA level <300 μmol/L (Table 3) . As the target value has been set at a sUA of < 300 μmol/L, expert consensus concurred that below this value the rate of crystal elimination is increased and the risk of developing tophi is reduced. In the study by Pascual and Sivera, 13 arthrocentesis was performed in 18 patients before initiation of ULT and it was found that crystals soon disappeared after a dramatic reduction of sUA. Although the current trend of "treating to target" is being emphasized, only a few have successfully achieved the goal. 13 The findings also suggest that sUA measurements do not precipitate allopurinol titration.
In patients who do not receive allopurinol, However, the presence of these comorbidities can also make management difficult and may implicate the efficacy of pharmacological therapy. With these recommendations in hand, it would help the practice to meet the standards set by the guidelines and also provide optimum care for gout patients in the future.
Learning Points
What is known already  Gout is a common occurrence in primary care and its incidence has been rising, affecting mainly males and those over 65 years of age.  If not managed appropriately, gout may contribute to renal and cardiovascular comorbidities and may cause permanent joint destruction.  Conservative treatments (i.e. lifestyle modifications) in combination with medical therapy (i.e. NSAIDs, colchicines and corticosteroids) have been the mainstay of gout management.  Allopurinol is commonly used as a prophylactic medication to reduce recurrent attacks.
What this study adds
 The BSR has released a set of guidelines to direct the appropriate management of gout.
However, we suspect that these are not being adhered to closely across primary care.  Patients on allopurinol should have their dosages reviewed in line with their sUA levels.
However, determining the optimal dose to prescribe to achieve good control of sUA levels is challenging.  Clearly there needs to be improvements in adherence to guidelines, especially in the area of monitoring sUA levels, follow-up and prescribing allopurinol where clinically indicated.
